| 摘要 |
<p>The present invention provides compositions and methods for the treatment of herpes virus infections. In one aspect, the invention provides a combination therapy for treating a herpes virus infection comprising the administration to a subject of an anti-herpes virus agent in combination with a cyclooxygenase-2 selective inhibitor. In another aspect, the invention provides a mono therapy for treating a herpes virus infection comprising administering a cyclooxygenase-2 selective inhibitor to a subject. Preferably, the cyclooxygenase-2 selective inhibitor is selected from the group consisting of celecoxib, deracoxib, valdecoxib, rofecoxib, lumiracoxib, etoricoxib, parecoxib, 2-(3, 4-difluoro-phenyl)-4 -(3-hydroxy-3 -methylbutoxy)-5 -`4- (methylsulphonyl) phenyl!-3(2H)- pyridazinone, and (S)-6, 8-dichloro-2- (trifluoromethyl) -2H-1-benzopyran-3 -carboxylic acid; and the anti-herpes virus agent selected from the group consisting of ganciclovir, foscarnet, cidofovir, acycloguanosine, tri-fluorothymidine, acyclovir, famciclovir, and valaciclovir.</p> |
